Obesity trials recruiting in Tennessee

All Obesity trials nationally

Cities in Tennessee

Recruiting trials in Tennessee

• A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
  NCT07351045 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Tennessee: Clarksville, Nashville
• A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
  NCT06143956 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Tennessee: Nashville
• A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM
  NCT07667803 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Tennessee: Franklin, Knoxville
• A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
  NCT06672549 · Phase: Phase 3 · Ages: 6 Years to 17 Years · Sex: All (male and female) · Tennessee: Nashville
• A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity
  NCT07639021 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Tennessee: Bristol, Kingsport, Nashville
• A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
  NCT07253285 · Phase: Phase 3 · Ages: 8 Years to 18 Years · Sex: All (male and female) · Tennessee: Memphis
• A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
  NCT07564414 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Tennessee: Jackson, Kingsport, Memphis, Morristown
• A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
  NCT07567001 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Tennessee: Greeneville, Jackson
• A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
  NCT07654374 · Phase: Phase 3 · Ages: 18 Years to 79 Years · Sex: All (male and female) · Tennessee: Nashville
• A Study of CSTI-500 in Patients With Prader-Willi Syndrome
  NCT07348601 · Phase: Phase 2 · Ages: 13 Years to 50 Years · Sex: All (male and female) · Tennessee: Nashville
• A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
  NCT07321886 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Tennessee: Nashville
• A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
  NCT07743450 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Tennessee: Memphis
• A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
  NCT07743463 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Tennessee: Memphis
• A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities
  NCT06672939 · Phase: Phase 3 · Ages: 12 Years to 17 Years · Sex: All (male and female) · Tennessee: Nashville
• A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee
  NCT07153471 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Tennessee: Knoxville
• A Study of PF-08653945 and PF-08653944 in Adults With Overweight or Obesity (SOLIS-1)
  NCT07575932 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Tennessee: Hendersonville
• A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment
  NCT06239116 · Phase: Phase 1, Phase 2 · Ages: 12 Years to 65 Years · Sex: All (male and female) · Tennessee: Nashville
• A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
  NCT07784725 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Tennessee: Kingsport
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MBX 4291 in Adult Participants With Obesity
  NCT07142707 · Phase: Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · Tennessee: Knoxville
• A Study to Improve Skeletal Muscle in Veterans With HIV
  NCT06845046 · Phase: Not applicable (e.g. observational or device study) · Ages: 20 Years to 80 Years · Sex: Male · Tennessee: Nashville
• A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)
  NCT06864026 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female) · Tennessee: Jackson, Murfreesboro
• A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
  NCT07589608 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Tennessee: Nashville
• A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
  NCT06857942 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female) · Tennessee: Smyrna
• AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight
  NCT07533175 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Tennessee: Chattanooga
• Atomoxetine in Melanocortin Obesity Syndrome
  NCT06899178 · Phase: Phase 2 · Ages: 6 Years and older · Sex: All (male and female) · Tennessee: Nashville
• Daily Eating Patterns for Total Health Study
  NCT06455995 · Phase: Not applicable (e.g. observational or device study) · Ages: 25 Years to 60 Years · Sex: All (male and female) · Tennessee: Knoxville
• EBT Fruit and Vegetable Prescription
  NCT05028205 · Phase: Not applicable (e.g. observational or device study) · Ages: 4 Years to 10 Years · Sex: All (male and female) · Tennessee: Knoxville
• Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
  NCT07654361 · Phase: Phase 3 · Ages: 18 Years to 79 Years · Sex: All (male and female) · Tennessee: Knoxville
• Efficacy and Safety of Oral KAI-7535 in Adult Participants Living With Obesity or Overweight With at Least 1 Weight-Related Comorbidity
  NCT07497880 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Tennessee: Knoxville
• Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
  NCT07284901 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Tennessee: Chattanooga, Memphis
• Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes
  NCT07284875 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Tennessee: Chattanooga
• Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
  NCT07037433 · Phase: Phase 3 · Ages: 45 Years to 99 Years · Sex: All (male and female) · Tennessee: Germantown, Knoxville, Powell, Tullahoma
• Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events
  NCT07607587 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Tennessee: Bristol
• Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
  NCT07684235 · Phase: Phase 3 · Ages: 18 Years to 99 Years · Sex: All (male and female) · Tennessee: Knoxville
• Gut Microbiota in Metabolic Surgery
  NCT05000996 · Phase: Not specified · Ages: 21 Years to 65 Years · Sex: All (male and female) · Tennessee: Nashville
• Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
  NCT07037459 · Phase: Phase 3 · Ages: 18 Years to 99 Years · Sex: All (male and female) · Tennessee: Jackson, Oak Ridge, Powell, Tullahoma
• Metabolic Effects of Angiotensin-(1-7)
  NCT02646475 · Phase: Phase 1 · Ages: 18 Years to 60 Years · Sex: All (male and female) · Tennessee: Nashville
• Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
  NCT06937086 · Phase: Phase 3 · Ages: 18 Years to 70 Years · Sex: All (male and female) · Tennessee: Cordova
• Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
  NCT06937099 · Phase: Phase 3 · Ages: 18 Years to 70 Years · Sex: All (male and female) · Tennessee: Cordova
• Relationship Between Aspirin Metabolism and Markers of Metabolic Dysfunction Among Pregnant Persons at Risk of Pre-eclampsia
  NCT06802861 · Phase: Not specified · Ages: 18 Years to 45 Years · Sex: Female · Tennessee: Knoxville
• Resistance Exercise and Incretin Mimetic for Cardiometabolic Health in Survivors of ALL With Obesity
  NCT07228741 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Tennessee: Memphis
• Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities
  NCT07752979 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Tennessee: Bristol, Knoxville, Nashville
• Sympathetic Mechanisms in Obesity-Crossover Design
  NCT05312892 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · Tennessee: Nashville
• The ADAPT Trial: Adapting Evidence-Based Obesity Interventions in Community Settings
  NCT06546696 · Phase: Not applicable (e.g. observational or device study) · Ages: 6 Years to 12 Years · Sex: All (male and female) · Tennessee: Nashville
• The Dose Trial: Dose Intensity of Behavioral Interventions for Childhood Obesity
  NCT06654323 · Phase: Not applicable (e.g. observational or device study) · Ages: 5 Years to 17 Years · Sex: All (male and female) · Tennessee: Nashville
• The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
  NCT05972564 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Tennessee: Nashville
• Tirzepatide in PWS, HO and GNSO
  NCT06901245 · Phase: Phase 4 · Ages: 18 Years to 26 Years · Sex: All (male and female) · Tennessee: Nashville
• Whole Foods for Teens: A Pilot Dietary Intervention to Reduce Body Adiposity in Adolescents With Obesity
  NCT06464497 · Phase: Not applicable (e.g. observational or device study) · Ages: 10 Years and older · Sex: All (male and female) · Tennessee: Nashville